ArticlePharmaceutical research2008
Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.
Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 140 citations in OpenAlex.
- Nanoparticulate CpG immunotherapy in RAO-affected horses: phase I and IIa study.Journal of veterinary internal medicine · 2015Trial
- Nasal Delivery of mRNA Using Thermoresponsive Gellable Aqueous Biphasic Systems.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Charting new frontiers in nanoparticle immunotoxicity: A perspective on current, emerging, and future approaches.Biochemical and biophysical research communications · 2025Review
- Unveiling nanoparticle-immune interactions: how super-resolution imaging illuminates the invisible.Nanoscale · 2025Review
- Shifting cold to hot tumors by nanoparticle-loaded drugs and products.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy.Journal of hematology & oncology · 2024Review
- Inhalative Nanoparticulate CpG Immunotherapy in Severe Equine Asthma: An Innovative Therapeutic Concept and Potential Animal Model for Human Asthma Treatment.Animals : an open access journal from MDPI · 2022Review
- Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems.Pharmaceutics · 2021Article
- Nanoparticle System Based on Amino-Dextran as a Drug Delivery Vehicle: Immune-Stimulatory CpG-Oligonucleotide Loading and Delivery.Pharmaceutics · 2020Article
- Macrophage-like THP-1 cells show effective uptake of silica nanoparticles carrying inactivated diphtheria toxoid for vaccination.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2020Article
- Immunomodulatory asthma therapy in the equine animal model: A dose-response study and evaluation of a long-term effect.Immunity, inflammation and disease · 2019Article
- Non-Viral Delivery System and Targeted Bone Disease Therapy.International journal of molecular sciences · 2019Review
- A comparison of nanoparticullate CpG immunotherapy with and without allergens in spontaneously equine asthma-affected horses, an animal model.Immunity, inflammation and disease · 2018Article
- Delivering safer immunotherapies for cancer.Advanced drug delivery reviews · 2017Review
- Article
- Non-invasive administration of biodegradable nano-carrier vaccines.American journal of translational research · 2017Review
- Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2015Review
- Multilayered Magnetic Gelatin Membrane Scaffolds.ACS applied materials & interfaces · 2015Article
- Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity.Carbohydrate research · 2015Article
- The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization.Human vaccines & immunotherapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCationized gelatin nanoparticles (GNPs) were used as carrier to improve delivery of immunostimulatory CpG oligonucleotides (CpG ODN) both in vitro and in vivo.
methodsUptake of CpG ODN-loaded cationized gelatin nanoparticles (CpG-GNPs) into murine myeloid dendritic cells (DCs) and their respective immunostimulatory activity was monitored. In vivo, induction of cytokine secretion by CpG-GNPs was measured. For experiments on primary human cells, prototypes of the three CpG ODN classes were adsorbed onto GNPs. Uptake and induction of proinflammatory cytokines were assessed in human plasmacytoid DCs and B cells, the only existing human target cells for CpG ODN.
resultsIn the murine system, gelatin nanoparticle formulations enhanced the uptake and immunostimulatory activity of CpG ODN both in vitro and in vivo. Furthermore, delivery by cationized gelatin nanoparticles of CpG ODN of the classes B and C to primary human plasmacytoid DCs increased production of IFN-alpha, a key cytokine in the driving of both the innate and adaptive immune responses.
conclusionGNPs can be used as a biodegradable and well tolerated carrier to deliver CpG ODN to their target cells and strongly increase activation of the immune system. This concept may be applied as novel adjuvant for antiviral and antitumoral vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.